Voriconazole-induced QT interval prolongation and torsades de pointes

Pediatrics International

Volumn 53, Issue 5, 2011, Pages 761-763

  Aypar, Ebru ^a   Kendirli, Tanil ^a   Tutar, Ercan ^a   Çiftçi, Ergin ^a   Ince, Erdal ^a   Ileri, Talia ^a   Atalay, Semra ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

arrhythmia; QT interval; QT interval prolongation; torsades de pointes; voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ASPARAGINASE; CASPOFUNGIN; CIPROFLOXACIN; CYTARABINE; DOXORUBICIN; IMATINIB; LIDOCAINE; MAGNESIUM; POTASSIUM; PREDNISOLONE; VINCRISTINE; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AORTA VALVE REGURGITATION; ARTICLE; ARTIFICIAL EMBOLISM; ASPERGILLOSIS; BRAIN HEMORRHAGE; CASE REPORT; CHILD; COUGHING; DEFIBRILLATION; DEVICE REMOVAL; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; FUNGAL ENDOCARDITIS; HEART VENTRICLE BIGEMINY; HEART VENTRICLE SEPTUM DEFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; LOADING DRUG DOSE; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSTHESIS INFECTION; QT PROLONGATION; RESPIRATORY FAILURE; SCHOOL CHILD; THORAX PAIN; TORSADE DES POINTES; TRICHOSPORON ASAHII;

EID: 80053535588     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2010.03321.x     Document Type: Article

References (12)

1. Towbin JA, Friedman RA,. Long QT syndrome. In:, Walsh EP, Saul JP, Triedman JK, (eds). Cardiac Arrhythmias in Children and Young Adults with Congenital Heart Disease. Lippincott Williams & Wilkins, Philadelphia, PA, 2001; 235-70.
2. Scott LJ, Simpson D,. Voriconazole: A review of its use in the management of invasive fungal infections. Drugs 2007; 67: 269-98.
3. Alkan Y, Haefeli WE, Burhenne J, Stein J, Yaniv I, Shalit I,. Voriconazole-induced QT interval prolongation and ventricular tachycardia: A non-concentration-dependent adverse effect. Clin. Infect. Dis. 2004; 39: e49-52.
4. Philips JA, Marty FM, Stone RM, Koplan BA, Katz JT, Baden LR,. Torsades de pointes associated with voriconazole use. Transpl. Infect. Dis. 2007; 9: 33-6.
5. Zimmermann M, Duruz H, Guinand O, et al,. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur. Heart J. 1992; 13: 1002-3.
6. Esch JJ, Kantoch MJ,. Torsades de pointes ventricular tachycardia in a pediatric patient treated with fluconazole. Pediatr. Cardiol. 2008; 29: 210-13.
7. Falagas ME, Rafailidis PI, Rosmarakis ES,. Arrhythmias associated with fluoroquinolone therapy. Int. J. Antimicrob. Agents 2007; 29: 374-9. (Pubitemid 46349590)
8. El-Sherif N,. T-wave alternans: A marker of vulnerability to ventricular tachyarrhythmias. In:, Raviele A, (ed). Cardiac Arrhythmias. Springer, Milan, 1995; 12-16.
9. Chao CL, Chen WJ, Wu CC, Lee YT,. Torsade de pointes and T-wave alternans in a patient with brainstem hemorrhage. Int. J. Cardiol. 1995; 51: 199-201.
10. Alehan D, Ceviz N, Celiker A,. Torsades de pointes associated with encephalitis. Turk. J. Pediatr. 1999; 41: 395-8.
11. FDA Antiviral Drugs Advisory Committee. Briefing Document for Voriconazole (Oral and Intravenous Formulations). [Accessed 4 October 2001]. Available from URL
12. Weiss J, Ten Hoevel MM, Burhenne J, et al,. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol. 2009; 49: 196-204.